{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia5mny3alxtu36fvbzazefljrwewybtbf36u3sxv7upecdscztpxu",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mf4lntsvvfp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicomrfailbd6xjxkaasstc5k4gnegjx5jz6mgvzn4k2qiqbxarfwu"
    },
    "mimeType": "image/jpeg",
    "size": 53318
  },
  "path": "/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/?utm_campaign=rss",
  "publishedAt": "2026-02-17T12:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Breaking News",
    "Business",
    "Pharma",
    "biotechnology",
    "drug development",
    "research",
    "STAT+"
  ],
  "textContent": "Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.",
  "title": "STAT+: Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial",
  "updatedAt": "2026-02-17T17:30:45.000Z"
}